OKYO Pharma plans 111-patient Phase 3 NCP trial

OKYO Pharma will present at the Cantor Global Healthcare Conference, highlighting FDA-supported plans to advance urcosimod into a global Phase 3 trial.

Rhea-AI Filing Summary

OKYO Pharma Ltd (OKYO), a clinical-stage biopharmaceutical company focused on neuropathic corneal pain (NCP) and anterior segment eye diseases, reported that it will participate in a fireside chat at the Cantor Global Healthcare Conference being held September 9-11, 2026.

The session, featuring Chief Medical Officer Flavio Mantelli and Chief Development Officer Gary Jacob, is scheduled for September 10 at 8:35 AM, moderated by Eric Fitzgerald of Cantor Fitzgerald, and the company will also be available for one-on-one meetings. OKYO notes that this appearance follows recent positive feedback from a U.S. FDA Type D meeting that validated its regulatory and clinical path forward for urcosimod, as well as the filing of its Annual Report reflecting a strengthened cash position.

OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for treating NCP.

Positive

• FDA Type D feedback validated urcosimod’s regulatory and clinical path, supporting OKYO Pharma’s plans to advance its neuropathic corneal pain program into a pivotal Phase 3 trial enrolling about 111 patients in the second half of the year.
• The company highlights the filing of its Annual Report reflecting a strengthened cash position, suggesting improved financial resources to support clinical development activities.

Negative

• None.

Key Figures

Conference dates: September 9-11, 2026 Fireside chat time: September 10, 2026 at 8:35 AM Planned Phase 3 trial enrollment: Approximately 111 patients +1 more

4 metrics

Conference dates September 9-11, 2026 Cantor Global Healthcare Conference schedule

Fireside chat time September 10, 2026 at 8:35 AM Scheduled session with OKYO executives

Planned Phase 3 trial enrollment Approximately 111 patients Global Phase 3 pivotal trial of urcosimod for neuropathic corneal pain

Trial dosing regimen Single-dose regimen Design of planned Phase 3 urcosimod trial

Key Terms

Type D meeting, pivotal clinical trial, neuropathic corneal pain, anterior segment eye diseases, +1 more

5 terms

Type D meeting regulatory

"follows recent positive feedback from its U.S. Food and Drug Administration (FDA) Type D meeting"

pivotal clinical trial medical

"plans to initiate a global Phase 3 pivotal clinical trial in the second half"

A pivotal clinical trial is a late-stage medical study designed to provide the main evidence regulators use to decide whether a drug or medical device can be approved and sold; think of it as the product’s final exam. For investors, the trial’s outcome is critical because a clear pass can unlock regulatory approval, market access and future revenue, while failure can halt commercialization and materially affect a company’s valuation.

neuropathic corneal pain medical

"developing investigational therapies for the treatment of neuropathic corneal pain (NCP)"

Neuropathic corneal pain is chronic, often severe eye pain caused by damage or malfunction in the tiny nerves of the cornea, where the eye surface can feel burning, stinging, or like something is in it despite little visible damage. It matters to investors because it represents a persistent, hard-to-treat medical need that drives demand for new drugs, diagnostics, devices and regulatory approvals, similar to how fixing a frayed electrical wire stops false alarm signals.

anterior segment eye diseases medical

"and anterior segment eye diseases, today announced participation"

Diseases of the anterior segment of the eye are medical conditions that affect the front part of the eye—including the cornea, iris, lens, and the front chamber—similar to damage or fogging on a car’s windshield that interferes with vision. They matter to investors because this category drives demand for drugs, surgical devices, diagnostic tools, and clinical trials; prevalence, regulatory approvals, and reimbursement decisions can directly affect companies’ revenues and valuations.

single-dose regimen medical

"to evaluate a single-dose regimen of urcosimod for the treatment of NCP"

A single-dose regimen is a treatment plan in which a medication or vaccine is administered just once to produce the intended protective or therapeutic effect, rather than through multiple injections or pills over days or weeks. It matters to investors because single-dose products can simplify distribution, lower treatment costs, improve patient adherence, and change market demand and regulatory review timelines—much like a one-time purchase versus an ongoing subscription.

FAQ

What did OKYO (OKYO) announce in this Form 6-K?

OKYO Pharma announced participation in a fireside chat at the Cantor Global Healthcare Conference on September 10, 2026, and noted recent positive FDA Type D feedback on urcosimod and an Annual Report reflecting a strengthened cash position.

When and where will OKYO (OKYO) present at the Cantor Global Healthcare Conference?

OKYO will participate in a fireside chat at the Cantor Global Healthcare Conference, held September 9-11, 2026. Its specific session is scheduled for Thursday, September 10 at 8:35 AM, moderated by Eric Fitzgerald of Cantor Fitzgerald.

What is the status of OKYO (OKYO) drug candidate urcosimod?

OKYO reports that recent U.S. FDA Type D meeting feedback validated its regulatory and clinical path forward for urcosimod, and the company plans a global Phase 3 pivotal trial in the second half of this year for neuropathic corneal pain.

How large is the planned Phase 3 trial for OKYO (OKYO) urcosimod?

The planned global Phase 3 pivotal clinical trial will enroll approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of neuropathic corneal pain.

What financial information did OKYO (OKYO) reference in this update?

OKYO referenced the filing of its Annual Report, which it states reflects a strengthened cash position. No specific financial figures are included in this disclosure.

What type of company is OKYO (OKYO)?

OKYO Pharma is a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain and anterior segment eye diseases, with its ordinary shares listed on the Nasdaq Capital Market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 07:01 AM Accepted by SEC EDGAR 09/08/2026 - 07:00 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

September 2026

Commission File Number: 001-41386

OKYO Pharma LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On September 8, 2026, OKYO Pharma LTD (the “Company”) issued this 6K announcing participation at the Cantor Global Healthcare Conference being held September 9-11, 2026.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, This report on Form 6-K is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (Reg. No. 333-293145)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	OKYO Pharma LTD
Date: September 8, 2026	By:	/s/ Keeren Shah
	Name:	Keeren Shah
	Title:	Chief Financial Officer

3

EXHIBIT INDEX

Exhibit No.		Description
99.1		News Announcement, dated September 8, 2026

4

Exhibit 99.1

OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference

London and New York, NY, September 8, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced participation at the Cantor Global Healthcare Conference being held September 9-11, 2026.

Details of the event are as follows:

Presenters: Flavio Mantelli, MD, PhD, Chief Medical Officer, Gary Jacob, PhD, Chief Development Officer

Date/Time: Thursday, September 10 at 8:35 AM ET

Moderator: Eric Fitzgerald, Cantor Fitzgerald

The Company will be available for one-on-one meetings during the conference.

The Company’s presence at the events follows recent positive feedback from its U.S. Food and Drug Administration (FDA) Type D meeting, which validated OKYO’s regulatory and clinical path forward for urcosimod, as well as the filing of its Annual Report reflecting a strengthened cash position.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.

For further information, please visit www.okyopharma.com.

For further inquiries:

OKYO Pharma Ltd

Paul Spencer

Business Development and Investor Relations

+44 (0) 207 495 2379

Email: info@okyopharma.com

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 6.3 KB
• EX-99 GRAPHIC 19.5 KB